TY - JOUR AU - Basile Stamatopoulos, AU - Nathalie Meuleman, AU - Cécile De Bruyn, AU - Karlien Pieters, AU - Philippe Mineur, AU - Christine Le Roy, AU - Stéphane Saint-Georges, AU - Nadine Varin-Blank, AU - Florence Cymbalista, AU - Dominique Bron, AU - Laurence Lagneaux, PY - 2012/04/05 Y2 - 2024/03/29 TI - AMD3100 disrupts the cross-talk between chronic lymphocytic leukemia cells and a mesenchymal stromal or nurse-like cell-based microenvironment: pre-clinical evidence for its association with chronic lymphocytic leukemia treatments JF - Haematologica JA - haematol VL - 97 IS - 4 SE - Articles DO - 10.3324/haematol.2011.052779 UR - https://haematologica.org/article/view/6278 SP - 608-615 AB - Background Interactions with the microenvironment, such as bone marrow mesenchymal stromal cells and nurse-like cells, protect chronic lymphocytic leukemia cells from spontaneous and drug-induced apoptosis. This protection is partially mediated by the chemokine SDF-1α (CXCL12) and its receptor CXCR4 (CD184) present on the chronic lymphocytic leukemia cell surface.Design and Methods Here, we investigated the ability of AMD3100, a CXCR4 antagonist, to sensitize chronic lymphocytic leukemia cells to chemotherapy in a chronic lymphocytic leukemia/mesenchymal stromal cell based or nurse-like cell based microenvironment co-culture model.Results AMD3100 decreased CXCR4 expression signal (n=15, P=0.0078) and inhibited actin polymerization/migration in response to SDF-1α (n=8, P